Zoe M. Weinstein, MD, MS

Assistant Professor, Medicine

Zoe Weinstein
617.414.7399
801 Massachusetts Ave Crosstown Center

Biography

Zoe M. Weinstein MD,MS, is a general internist and a graduate of the Boston University Addiction Medicine Fellowship. Her clinical work and research are focused on long-term Office-Based Addiction Treatment (OBAT) with buprenorphine, as well as the integration of addiction treatment with primary care and inpatient medical care. She is the director of Boston Medical Center’s Addiction Consult Service and Associate Director of the Grayken Addiction Medicine Fellowship.

Other Positions

  • Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University School of Medicine

Education

  • University of California San Francisco, MD
  • Columbia University, BA

Publications

  • Published on 3/1/2022

    Peterkin A, Davis CS, Weinstein Z. Permanent Methadone Treatment Reform Needed to Combat the Opioid Crisis and Structural Racism. J Addict Med. 2022 Mar-Apr 01; 16(2):127-129. PMID: 33758114.

    Read at: PubMed
  • Published on 3/1/2022

    Kimmel SD, Rosenmoss S, Bearnot B, Weinstein Z, Yan S, Walley AY, Larochelle MR. Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. Health Aff (Millwood). 2022 03; 41(3):434-444. PMID: 35254930.

    Read at: PubMed
  • Published on 1/1/2022

    Peterkin A, Laks J, Weinstein ZM. Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder. Med Clin North Am. 2022 Jan; 106(1):61-80. PMID: 34823735.

    Read at: PubMed
  • Published on 11/30/2021

    Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health. 2022 01; 7(1):e56-e64. PMID: 34861189.

    Read at: PubMed
  • Published on 11/1/2021

    Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451. PMID: 33298750.

    Read at: PubMed
  • Published on 11/1/2021

    Peeler CE, Gorgy M, Sadlak N, Sathe S, Tamashunas N, Fiorello MG, Cabral H, Paasche-Orlow MK, Weinstein ZM. A Pilot Study of Automated Pupillometry in the Treatment of Opioid Use Disorder. J Addict Med. 2021 Nov-Dec 01; 15(6):477-483. PMID: 33323697.

    Read at: PubMed
  • Published on 9/1/2021

    Montalvo C, von Horn A, Lane CE, Weinstein ZM, Sharma M, Suzuki J. Precipitated Withdrawal, Delirium, and Cerebellar Stroke: The Pharmacology of Buprenorphine Induction in Non-pharmaceutical Fentanyl and the Neuropsychiatric Manifestations of Cerebellar Stroke. Harv Rev Psychiatry. 2021 Sep-Oct 01; 29(5):370-377. PMID: 34524778.

    Read at: PubMed
  • Published on 8/30/2021

    Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, Turnbull J. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021 12; 98:103400. PMID: 34469781.

    Read at: PubMed
  • Published on 4/28/2021

    Harris MTH, Peterkin A, Bach P, Englander H, Lapidus E, Rolley T, Weimer MB, Weinstein ZM. Correction to: Adapting inpatient addiction medicine consult services during the COVID-19 pandemic. Addict Sci Clin Pract. 2021 Apr 28; 16(1):25. PMID: 33910637.

    Read at: PubMed
  • Published on 4/20/2021

    Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021 07 01; 224:108703. PMID: 33964730.

    Read at: PubMed

View 23 more publications: View full profile at BUMC

View all profiles